The Alzheimer's Drug Discovery Foundation (ADDF) is a New York-based nonprofit founded in 1998 by Leonard A. and Ronald S. Lauder. It is the world's only public charity solely dedicated to funding drug and diagnostic development for Alzheimer's disease and related dementias. The ADDF operates through a venture philanthropy model, making equity or convertible note investments in biotechs, and funding academic labs through milestone-based grants.

It employs six in-house expert neuroscientists for due diligence. Since 1998, ADDF has awarded over $360 million across 760+ programs and clinical trials in 21 countries. Its Diagnostics Accelerator (DxA), a $100M initiative, funds diagnostic biomarker and digital health tools. Notable investments include RetiSpec (AI-based retinal Alzheimer's diagnostics), Therini Bio (neuroinflammation immunotherapy), Linus Health (digital cognitive assessment), and AcuraStem (ALS/FTD platform). Investments range from $100K to $3M+.